Navigation Links
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions in Triglycerides and APOC-III in Patients with High Triglycerides and Type 2 Diabetes
Date:6/23/2013

ith high triglycerides and type 2 diabetes. ISIS-APOCIIIRx demonstrated a good safety profile in the study and was well tolerated in all subjects with no discontinuations, no clinically meaningful elevations in liver enzymes, no flu-like symptoms, no significant adverse events, and a low incidence of mild injection site reactions which were infrequent and typically resolved within a day or two.  

"Our focus is to bring ISIS-APOCIIIRx to the market for patients with severe hypertriglyceridemia.  These are patients who cannot reduce their triglycerides to safe levels with currently available medicines. We plan to report data from our ongoing Phase 2 program in very high triglyceride patients later this summer evaluating ISIS-APOCIIIRx in combination with fibrates and as a monotherapy," said Richard Geary, Ph.D., senior vice president of clinical development at Isis. "In the study we are reporting today, we observed rapid and prolonged reductions of apoC-III, triglycerides and other lipid parameters, as well as improvements in glucose control and insulin sensitivity. These data suggest that ISIS-APOCIIIRx could provide therapeutic benefit to patients with high triglycerides who are insulin insensitive, including patients who are obese or have type 2 diabetes. In addition, the positive effect of ISIS-APOCIIIRx on all atherogenic lipid parameters measured and the observed increase in HDL, significantly enhances the potential profile of the drug."

In this study, 11 patients were randomized 2:1 to receive a 300 mg dose of ISIS-APOCIIIRx or placebo via weekly subcutaneous injections for 13 weeks.  Patients entering the study had a mean apoC-III level of 14.3 mg/dL, a mean triglyceride level of 259 mg/dL and a mean HDL level of 43.4 mg/dL. 

ISIS-APOCIIIRx is an antisense drug that targets apoC-III, a gene produced in the l
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... July 11, 2014 ... Safety & Health Expo 2014 were a ... to London , plus ... exhibition.          (Logo: ... )      (Photo: ...
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
(Date:7/13/2014)... July 13, 2014 If Dr. Lawrence Power ... has just launched at http://www.HealthYourself101.com will expand people’s ... , Power has set out to provide a health ... that’s actually – dare we say it? – entertaining to ... Power, “aims to engage the remote learner – the solitary ...
(Date:7/12/2014)... to the new market research report "Security and Surveillance ... - Global Forecasts and Analysis to 2014 - 2020", ... estimated to be $6.08 billion in 2014 and are ... $8.61 billion by 2020. , Browse more than 93 ... pages and in-depth TOC on "Security and Surveillance Radar ...
(Date:7/12/2014)... The Passenger Information System market is estimated to grow ... 2019, at an expected CAGR of 26.5% for the ... infrastructure in North America is well developed and network ... of the region. The growing ridership figures in public ... are driving the North American Passenger Information System market ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... no way to guarantee that a surgical technique used to ... won,t increase the risk of spreading cancer to other parts ... The advisory panel to the Food and Drug Administration also ... laparoscopic power morcellation -- should sign a written consent stating ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The Security ... in 2013 to $3,376.6 million by 2019, at an ... and 2019. The challenges to counter the increasing number ... existence of outdated cyber defense systems in organizations are ... innovating and remodeling their existing architecture to develop better ...
Breaking Medicine News(10 mins):Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... Anniversary of Delivering Innovative Solutions to Improve the ... ATLANTA, June 10 Craneware, Inc., (AIM: CRW.L), ... the U.S. healthcare market, today announced that key ... presentations during the Healthcare Financial Management Association,s (HFMA,s) ...
... an increasing demand for massage therapy education in the Chicago ... the Prologis Business Park in Woodridge, Ill. Cortiva is ... , , Cortiva Institute offers a diploma in ... length (56 quarter credits) and includes hands-on courses in Practical ...
... Addresses Medical Research Compliance Requirements , , AUSTIN, ... of medical research management software for the Life Sciences ... product line, the Biosafety Solution. , , TOPAZ ... process, from protocol inception to approval, as required by ...
... EDISON, N.J., June 10 BellaDerm, the first human ... contouring procedures, is being introduced today by MTF, the ... , , BellaDerm is a unique acellular ... tissue has properties that are very appealing to plastic ...
... ALTOS, Calif., June 10 InteKrin Therapeutics Inc presented ... Association annual meeting in New Orleans demonstrating that once ... consistent with maximal dose thiazolidinedione (TZD) therapy but with ... The 4 week double blind placebo controlled study of ...
... RealAge and Co-Author of the YOU Book Series - Urges America to ... , , SAN DIEGO, June 10 A new survey released ... pressure are not at all familiar with the role of the renin ... about 9 out of 10 adults with high blood pressure (89%) both ...
Cached Medicine News:Health News:Craneware to Highlight Best Practices for Optimizing Revenue Capture Processes in Two Seminar Presentations during HFMA's 2009 ANI: The Healthcare Finance Conference 2Health News:Cortiva Institute to Open Branch Location in Woodridge, IL 2Health News:TOPAZ Technologies Introduces Biosafety Software Solution 2Health News:TOPAZ Technologies Introduces Biosafety Software Solution 3Health News:BellaDerm(TM), a Unique Human Skin Tissue Implant for Facial and Body Contouring, is Introduced by MTF 2Health News:InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting 2Health News:InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting 3Health News:New Survey Finds Majority of Adults Don't Understand a Key Source of High Blood Pressure 2Health News:New Survey Finds Majority of Adults Don't Understand a Key Source of High Blood Pressure 3Health News:New Survey Finds Majority of Adults Don't Understand a Key Source of High Blood Pressure 4Health News:New Survey Finds Majority of Adults Don't Understand a Key Source of High Blood Pressure 5Health News:New Survey Finds Majority of Adults Don't Understand a Key Source of High Blood Pressure 6
... Whether for bypass grafting or creation of ... placed tissue tunnel is of the utmost ... is the answer for those seeking a ... configuration minimizes the risk of twisting or ...
... GORE-TEX ACUSEAL Cardiovascular Patch utilizes ... to "seal" around penetrating suture ... by as much as 88 ... improved suture retention, multi-directional strength ...
... Stretch Vascular Grafts have met the ... procedures. Recognized for exceptional performance and ... of renowned surgeons worldwide. These grafts ... the spread of infection, and ensure ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
Medicine Products: